Loading
Email Algynomics
Algynomics Home

Algynomics - Personalized Pain Medications and Diagnostics

  • 2009
    Algynomics finalizes an alliance with Eli Lilly & Co to study genetic associations in osteoarthritis and lower back pain with the goal of identifying phenotypic and genetic markers of duloxetine responses.
  • 2009
    Algynomics furthers its alliance with Orthogen, Inc. in the area of orthopedic medicine and therapeutics specific to osteoarthritis with the goal of identifying phenotypic and genetic markers of Orthokine responses.
  • 2009
    Algynomics continues to work with Beckman Coulter Genomics, formerly Cogenics, to conduct genotyping studies of biological samples.  Beckman Coulter Genomics is the sole provider of Algynomics’s proprietary Pain Research Panel. 
  • 2008
    Algynomics and Pfizer, Inc. finalize an alliance agreement to conduct a genome wide association with the goal of identifying new therapeutic targets for the treatment of painful osteoarthritis.
  • September 2007
    Clinical Data Inc. launches Algynomics' genetic Pain Research Panel: Press Release.
  • August 2007
    Dr. Samuel McLean joins Algynomics as Chief Medical Officer and will coordinate the development of therapeutic trials.
  • July 2007
    Algynomics and Pfizer Inc. enter into a research collaboration in pain genetics.
  • February 2007
    Algynomics and Orthogen Inc. establish an alliance in individualized orthopedic medicine: Press Release.
  • December 2006
    Scientific founders publish a newly discovered genetic mechanism that partially explains chronic pain conditions in the December 22nd issue of Science: Press Release.
  • November 2006
    Dr. Richard Gracely joins Algynomics and will coordinate the design and analysis of clinical pain studies.
  • October 2006
    Scientific founders co-publish a new gene discovery that diminishes pain perception in humans in the October 22nd issue of Nature Medicine: Press Release.
  • October 2006
    Algynomics Inc. enters into a first-of-its-kind agreement with Clinical Data Inc. to market and commercialize proprietary pain genetic markers and test purposes: Press Release.
  • January 2006
    Dr. Roger Fillingim joins Algynomics and will coordinate the development of Pain Diagnostic and Treatment medical devices that integrate genetic tests with neurological and psychological determinants of chronic pain conditions.
  • November 2005
    Algynomics Inc. enters into a landmark licensing agreement with the University of North Carolina. The agreement provides Algynomics with the exclusive rights to develop and market proprietary genetic pain markers owned and patented (pending) by the University of North Carolina.
  • August 2005
    Algynomics Inc. enlists the services of Mr. David R. LaVance as General Manager and Director of Business Development.
  • May 2005
    Algynomics Inc. enlists the legal services of Mr. Bill Wofford and Hutchinson Law Group.
  • March 2005
    Algynomics is Incorporated by Scientific Founders Dr. William Maixner and Dr. Luda Diatchenko.